Can a Point-of-Care Troponin I Assay be as Good as a Central Laboratory Assay? A MIDAS Investigation
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: We aimed to compare the diagnostic accuracy of the Alere Triage Cardio3 Tropinin I (TnI) assay (Alere, Inc., USA) and the PathFast cTnI-II (Mitsubishi Chemical Medience Corporation, Japan) against the central laboratory assay Singulex Erenna TnI assay (Singulex, USA). Methods: Using the Markers in the Diagnosis of Acute Coronary Syndromes (MIDAS) study population, we evaluated the ability of three different assays to identify patients with acute myocardial infarction (AMI). The MIDAS dataset, described elsewhere, is a prospective multicenter dataset of emergency department (ED) patients with suspected acute coronary syndrome (ACS) and a planned objective myocardial perfusion evaluation. Myocardial infarction (MI) was diagnosed by central adjudication. Results: The C-statistic with 95% confidence intervals (CI) for diagnosing MI by using a common population (n=241) was 0.95 (0.91-0.99), 0.95 (0.91-0.99), and 0.93 (0.89-0.97) for the Triage, Singulex, and PathFast assays, respectively. Of samples with detectable troponin, the absolute values had high Pearson (RP) and Spearman (RS) correlations and were RP =0.94 and RS=0.94 for Triage vs Singulex, RP =0.93 and RS=0.85 for Triage vs PathFast, and RP =0.89 and RS=0.73 for PathFast vs Singulex. Conclusions: In a single comparative population of ED patients with suspected ACS, the Triage Cardio3 TnI, PathFast, and Singulex TnI assays provided similar diagnostic performance for MI.
Abstract
Background: We aimed to compare the diagnostic accuracy of the Alere Triage Cardio3 Tropinin I (TnI) assay (Alere, Inc., USA) and the PathFast cTnI-II (Mitsubishi Chemical Medience Corporation, Japan) against the central laboratory assay Singulex Erenna TnI assay (Singulex, USA). Methods: Using the Markers in the Diagnosis of Acute Coronary Syndromes (MIDAS) study population, we evaluated the ability of three different assays to identify patients with acute myocardial infarction (AMI). The MIDAS dataset, described elsewhere, is a prospective multicenter dataset of emergency department (ED) patients with suspected acute coronary syndrome (ACS) and a planned objective myocardial perfusion evaluation. Myocardial infarction (MI) was diagnosed by central adjudication. Results: The C-statistic with 95% confidence intervals (CI) for diagnosing MI by using a common population (n=241) was 0.95 (0.91-0.99), 0.95 (0.91-0.99), and 0.93 (0.89-0.97) for the Triage, Singulex, and PathFast assays, respectively. Of samples with detectable troponin, the absolute values had high Pearson (RP) and Spearman (RS) correlations and were RP =0.94 and RS=0.94 for Triage vs Singulex, RP =0.93 and RS=0.85 for Triage vs PathFast, and RP =0.89 and RS=0.73 for PathFast vs Singulex. Conclusions: In a single comparative population of ED patients with suspected ACS, the Triage Cardio3 TnI, PathFast, and Singulex TnI assays provided similar diagnostic performance for MI.
참고문헌 (17)
- Guttmann A, "Association between waiting times and short term mortality and hospital admission after departure from emergency department: population based cohort study from Ontario, Canada", BMJ, 342, pp.d2983~ (2011)
- Sprivulis PC, "The association between hospital overcrowding and mortality among patients admitted via Western Australian emergency departments", Med J Aust, 184, pp.208~212 (2006)
- Diercks DB, "Prolonged emergency department stays of non-ST-segment elevation myocardial infarction patients are associated with worse adherence to the American College of Cardiology", American Heart Association guidelines for management and increased adverse events, 2007, pp.50, 489~496
- Pines JM, "The association between emergency department crowding and adverse cardiovascular outcomes in patients with chest pain", Acad Emerg Med, 16, pp.617~625 (2009)
- Pines JM, "Emergency department crowding is associated with poor care for patients with severe pain", Ann Emerg Med, 51, pp.1~5 (2008)
- Gaze D, "The use of a quantitative point of care system greatly reduces the turnaround time of cardiac marker determination", Point of Care, 3, pp.156~158 (2004)
- Singer AJ, "Point-of-care testing reduces length of stay in emergency department chest pain patients", Ann Emerg Med, 45, pp.587~591 (2005)
- Peacock WF, "Myeloperoxidase in the diagnosis of acute coronary syndromes: the importance of spectrum", Am Heart J, 162, pp.893~899 (2011)
- Thygesen K, "Third universal definition of myocardial infarction", J Am Coll Cardiol, 60, pp.1581~1598 (2012)
- Cardio3 Package Insert, "22900enEU Rev. A. 51 Sawyer Road, Suite 200", Alere Inc, ~ (2010)
- "Pathfast package insert"[URL]
- "Erenna Cardiac Troponin-I Immunoassay Kit 05-0288-02 Data Sheet. 1650 Harbor Bay Parkway, Suite 200", Singulex, Inc, ~ (2010)
- Bonaca MP, "Evaluation of the diagnostic performance of current and next-generation assays for cardiac troponin I in the BWH-TIMI ED Chest Pain Study", Eur Heart J Acute Cardiovasc Care, 2(3), pp.195~202 (2013)
- Apple FS, "Determination of 19 cardiac troponin I and T assay 99th percentile values from a common presumably healthy population", Clin Chem, 58, pp.1574~1581 (2012)
- Apple FS, "Defining the serum 99th percentile in a normal reference population measured by a high-sensitivity cardiac troponin I assay", Clin Biochem, 43, pp.1034~1036 (2010)
- "National Hospital Ambulatory Medical Care Survey: 2006 emergency department summary" (2008)[URL]
- Than M, "A 2-h diagnostic protocol to assess patients with chest pain symptoms in the Asia-Pacific region (ASPECT): a prospective observational validation study", Lancet, 377, pp.1077~1084 (2011)